Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Aug 1;11(8):704.
doi: 10.3390/v11080704.

Human Antimicrobial Peptides as Therapeutics for Viral Infections

Affiliations
Review

Human Antimicrobial Peptides as Therapeutics for Viral Infections

Aslaa Ahmed et al. Viruses. .

Abstract

Successful in vivo infection following pathogen entry requires the evasion and subversion of multiple immunological barriers. Antimicrobial peptides (AMPs) are one of the first immune pathways upregulated during infection by multiple pathogens, in multiple organs in vivo. In humans, there are many classes of AMPs exhibiting broad antimicrobial activities, with defensins and the human cathelicidin LL-37 being the best studied examples. Whereas historically the efficacy and therapeutic potential of AMPs against bacterial infection has been the primary focus of research, recent studies have begun to elucidate the antiviral properties of AMPs as well as their role in regulation of inflammation and chemoattraction. AMPs as therapeutic tools seem especially promising against emerging infectious viral pathogens for which no approved vaccines or treatments are currently available, such as dengue virus (DENV) and Zika virus (ZIKV). In this review, we summarize recent studies elucidating the efficacy and diverse mechanisms of action of various classes of AMPs against multiple viral pathogens, as well as the potential use of human AMPs in novel antiviral therapeutic strategies.

Keywords: antiviral strategies; cathelicidins; defensins; hepcidins; human antimicrobial peptides; transferrins.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

References

    1. Agier J., Efenberger M., Brzezinska-Blaszczyk E. Cathelicidin impact on inflammatory cells. Cent. Eur. J. Immunol. 2015;40:225–235. doi: 10.5114/ceji.2015.51359. - DOI - PMC - PubMed
    1. De la Fuente-Nunez C., Silva O.N., Lu T.K., Franco O.L. Antimicrobial peptides: Role in human disease and potential as immunotherapies. Pharmacol. Ther. 2017;178:132–140. doi: 10.1016/j.pharmthera.2017.04.002. - DOI - PubMed
    1. Wang G. Human antimicrobial peptides and proteins. Pharmaceuticals. 2014;7:545–594. doi: 10.3390/ph7050545. - DOI - PMC - PubMed
    1. Bahar A.A., Ren D. Antimicrobial peptides. Pharmaceuticals. 2013;6:1543–1575. doi: 10.3390/ph6121543. - DOI - PMC - PubMed
    1. Mulder K.C., Lima L.A., Miranda V.J., Dias S.C., Franco O.L. Current scenario of peptide-based drugs: The key roles of cationic antitumor and antiviral peptides. Front. Microbiol. 2013;4:321. doi: 10.3389/fmicb.2013.00321. - DOI - PMC - PubMed

Publication types

MeSH terms

Substances